I know its hypothetical at this point but do you have any thoughts on how Teva would play things out in the scenario where 1 or 2 (but no more) fully substitutable generics come to market. It would seem the Lovenox scenario would be a good model but I am not sure if Teva would have an alternative plan of action. For what its worth I am in the camp that believes they'll try to maximize revenue so we won't see a price war though I could see them go after another MS drug (XNPT?)
Market Data 
Markets 
AI
